Partnering Strategy


Ethris is actively seeking to forge strategic partnerships, joint ventures, and licensing arrangements with companies, small and large, that share our vision of advancing the development of innovative mRNA-based therapies. Of interest are:

Out-licensing Opportunities

Technology Collaborations

Product-development Partnerships

Please contact regarding any partnering opportunities.


Current Partnerships


Ethris has established a number of strategic collaborations to further enable the development of mRNA-based therapies, including the ones described below.

Ethris has an existing collaboration with the laboratory of Prof. Heymut Omran at the Munster University Hospital aimed at studying the impact of Ethris’ therapeutic mRNA strategy on lung diseases. More specifically, the joint research project is focused on application of Ethris’ SNIM®RNA technology in models of primary ciliary dyskinesia (PCD), including evaluation of ETH42, a first-in-class SNIM®RNA product in preclinical development. In 2019, the collaboration was further expanded with the receipt of a research grant by the Central Innovation Program for SMEs (ZIM) for rare pulmonary disease research.

Academic and Private Research Collaborations

Ethris and its partners 20Med Therapeutics, the AO Research Institute Davos and Paracelsus Medical University have received a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis. The Eurostars program is managed by the EUREKA organization and is supported by the European Union under the Horizon 2020 Framework Program.

Ethris is also part of the consortium REANIMA led by the Spanish Centro Nacional de Investigaciones Cardiovasculares (CNIC). The central goal of the REANIMA project is to explore novel therapeutic strategies in cardiac diseases by activating endogenous regenerative pathways.

Ethris has also joined the cmRNAbone consortium of 11 European partners working to develop chemically modified RNAs and a specific vector delivery system as a novel bone regenerative therapy for trauma and osteoporosis patients. The partners will receive EUR 6.3 million funding from the European Union’s Horizon 2020 Framework Program.

Get in touch.